Healthcare Provider Webinar: Biologics & Biosimilars – An Overview for Healthcare Providers In the treatment of osteoporosis, biologic and biosimilar medications may be provided as part of a treatment plan. […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]

Privacy Policy Our Commitment Osteoporosis Canada is committed to protecting the privacy of the personal information of its members, customers and other stakeholders. We value the trust of those we deal […]

No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]